Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | BioInformatics Reports | Capitalizing on New Opportunities for Stem Cell Products

Capitalizing on New Opportunities for Stem Cell Products

As a result of the March 9, 2009 reversal of the 2001 restrictions on federal funding of human embryonic stem cell research, suppliers of stem cell related products are in need of a fast, accurate assessment of new opportunities in the stem cell products market. Capitalizing on New Opportunities for Stem Cell Products was designed to provide estimates on market share, projected growth of the stem cell research products market, types and species of stem cells scientists intend to use, suppliers – and level of satisfaction with – stem cell media, unmet product needs and more. Beyond providing an understanding of the current stem cell products market, this report will help identify the new/expanding stem cell research opportunities as a result of the change in the current administration’s policies regarding human embryonic stem cells research.

Report #09-002

Publication Date: April 2009

Page Count: 263

Print Copy: $3,200

Company-wide Electronic Copy (includes print copy): $5,200

plus Data Set: an additional $1,200

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions